Clopidogrel in the management of ischemic heart disease

Heart Disease

Volumn 5, Issue 2, 2003, Pages 144-152

  Cavusoglu, Erdal ^a,c,d   Cheng, Judy ^b   Bhatt, Rajat ^a   Kunamneni, Prabhakara B ^a   Marmur, Jonathan D ^d   Eng, Calvin ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Downstate Health Sciences University   (United States)

Author keywords

Brachytherapy; Clopidogrel; Thienopyridines; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRACHYTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE COURSE; DRUG MECHANISM; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; RESTENOSIS; REVIEW; RISK; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; STROKE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HUMANS; MOLECULAR STRUCTURE; MYOCARDIAL ISCHEMIA; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE;

EID: 0038713298     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000061697.22030.e5     Document Type: Review

References (48)

1. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998;97:1195-1206.
2. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. Circulation. 1998; 97:1876-1887.
3. 2001 Heart and Stroke Statistics. Available at: http://www.american-heart.org/statistics/index.html. Accessed on Feb 16, 2002.
4. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12(1):56-62.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326(4):242-50.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326(5):310-8.
7. Arbustini E, Morbini P, Dal Bello B, et al. From plaque biology to clinical setting. Am Heart J. 1999;138:S55-S60.
8. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
9. Shah PK, Moreno P, Falk E. Pathophysiology of plaque rupture. J Vasc Med Biol. 1995;5:244-258.
10. Burke AP, Farb A, Malcolm GT, et al. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N Engl J Med. 1997;336:1276-1281.
11. Quinn MJ, FitzGerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100(15):1667-72.
12. PLAVIX Prescribing Information. Bristol-Myers Squibb/Sanofi-Synthelabo Inc. Pharmaceuticals Partnership, New York, 2003.
13. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerosic patients. Thromb Haemost. 1996;76:939-43.
14. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med. 1992;326:1406-1416.
15. Ridker PM, Manson JE, Gaziano M, et al. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med. 1991;114:835-839.
16. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-60.
17. Baiger C, Collins R, Appleby P, et al, for the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year-survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both or either. BMJ. 1998;316(7141):1337-43.
18. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
19. Lewis H, Davis JW, Archibald D, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Eng J Med. 1983;309:396-403.
20. Cairns J, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Eng J Med. 1985;313:1369-1375.
21. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction 2002 updated guidelines. Available at: http://www.americanheart.org/downloadable/heart/ 1016214837537UANSTEM12002Web.pdf. Accessed July 1, 2002.
22. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339.
23. The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
24. Plavix (Clopidogrel) prescribing information. Available at:http://www-plavixrx.com/pi.html. Accessed August 21, 2002.
25. Mehta SR, Yusuf S, Peter RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33.
26. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary artery disease. N Engl J Med. 2002;346:1800-6.
27. Popma JJ, Magnus Ohman E, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001; 119(1):321S-336S.
28. Muller C, Buttner HJ, Peterson J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after placement of coronary-artery stents. Circulation. 2000;101:590-3.
29. Bertrand ME, Rupprescht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation. 2000;102:624-9.
30. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39(1):9-14.
31. Fischman DL, Leon MB, Baim DS, et al, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
32. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol. 2002;39(2):183-93.
33. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336:1697-1703.
34. Waksman R, White RL, Chan RC, et al. Intracoronary gamma radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 2000;101:2165-2171.
35. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344:250-256.
36. Waksman R, Bhargava B, White L, et al. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation. 2000;101: 1895-1898.
37. Waksman R, Bhargava B, Mintz GS, et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol. 2000;36:65-68.
38. Waksman R. Late thrombosis after radiation: sitting on a time bomb. Circulation. 1999;100:780-782.
39. Costa MA, Sabate M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation. 1999;100:789-792.
40. Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary γ-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation. 2001; 103(19):2332-5.
41. Ahmed JM, Mintz GS, Waksman R, et al. Serial intravascular ultrasound analysis of edge recurrence after intracoronary gamma radiation treatment of native artery in-stent restenosis lesions. Am J Cardiol. 2001; 87(10):1145-9.
42. Ahmed JM, Mintz GS, Waksman R, et al. Serial intravascular ultrasound assessment of the efficacy of intracoronary gamma-radiation therapy for preventing recurrence in very long, diffuse, in-stent restenosis lesions. Circulation. 2001;104(8):856-9.
43. Waksman R, Ajani AE, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing γ-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 Versus WRIST PLUS. Circulation. 2002;106(7):776-8.
44. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867-73.
45. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
46. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104: 2007-11.
47. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
48. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20.